Ataxia-Telangiectasia (A-T) is a rare genetic disorder with an incidence of approximately three in one million births. Patients with A-T often end up in a wheelchair by the age of ten and have a life expectancy of 25 years. Approximately 40 children in Australia currently have A-T.

Research Objectives

Status

Current

Recruitment

Closed

Patient Group

Patients with Ataxia-Telangiectasia (AT)

Study location

Wesley Research Institute

Phase

2

Study type

Investigator Initiated

    Lead investigator    
            Prof David Coman        

        Clinical trial coordinator		
				Sarah Harriman			

Technical title

A Phase 2A/2B placebo-controlled randomised clinical trial to test the ability of triheptanoin to protect primary airway epithelial cells obtained from patients with ataxia-telangiectasia against death induced by glucose deprivation.

About this research project

This genetic disorder leads to ataxia; the inability to walk, talk and use fine motor skills because of the neurological impairment. A-T patients also suffer from cystic-fibrosis-like lung disease due to immunodeficiency as well as cancer accounting for a high death rate.

The symptoms of A-T are described as the ‘worst parts’ of cerebral palsy, cystic fibrosis and muscular dystrophy with a high risk of cancer and lung disease. There is unfortunately no effective therapy for this illness.

This study will investigate the use of Triheptanoin, a dietary fat supplement which has the potential to boost energy metabolism and significantly improve neurological symptoms. This trial has given families of patients the hope that they are able to have their children for longer by slowing down the progression of the disease.

Latest News

Going Gluten Free – Pratical Tips for Coeliac Disease Management

Living with coeliac disease requires significant lifestyle changes. At Wesley Research Institute, we understand how overwhelming this journey can feel, whether you are newly diagnosed or supporting a loved one. In this article, we’ll share practical, research-backed tips to help both coeliac patients and their support networks navigate this transition with confidence.

Research Advisory Board

We welcome Dr John Rivers, Professor Janet Hardy, Professor Jennifer Byrne, Professor John Prins, Professor Steven Lane, Professor Cathy Mihalopoulos and Professor Jill Francis to our newly established Research Advisory Board.

Pulmonary Hypertension team’s visit to Saudi Arabia

Wesley Research Institute researcher Dr John Feenstra and Clinical Trial Coordinator Bronwen Field, had the privilege of attending the 18th Annual Scientific Meeting of the Saudi Arabia Pulmonary Hypertension Society recently.

1 2 3 … 20 Next »

Rare Diseases

Ataxia-Telangiectasia (AT) Study